









# Aggregate Report writing for Regulatory Compliance

Unit Code: LFS/N0708

Version: 1.0

NSQF Level: 5.5

Life Sciences Sector Skill Development Council || # 14, Rear 2nd Floor, Palam Marg, Vasant Vihar New Delhi-110057 || email:ANSHUL.SAXENA@LSSSDC.IN









#### **Description**

This NOS gives an overview about how to Prepare and compile Aggregate Reports (PSURs, PBRERs, PADERs) for Regulatory Compliance

#### Scope

The scope covers the following:

- life sciences industry and Aggregate Reports
- Report Structure and Writing Skills for pharmacovigilance reporting.
- Signal Detection and Evaluation for Pharmacovigilance
- Risk Minimization and Compliance for Pharmacovigilance
- Application and Emerging Technologies For Pharmacovigilance

#### **Elements and Performance Criteria**

#### Life sciences industry and Aggregate Reports

To be competent, the user/individual on the job must be able to:

- **PC1.** analyze a sample Aggregate Report and discuss a case study on regulatory compliance in pharmacovigilance
- **PC2.** outline data sources and their management in pharmacovigilance

Report Structure and Writing Skills for pharmacovigilance reporting

To be competent, the user/individual on the job must be able to:

- **PC3.** submit a written assignment with sections of Aggregate Reports based on provided templates to demonstrate their understanding of report structure and regulatory writing.
- **PC4.** Participate in group exercises to collaboratively create a comprehensive Aggregate Report section, which will be evaluated for completeness and regulatory compliance.
- **PC5.** explore best practices in writing skills for regulatory compliance

Signal Detection and Evaluation for Pharmacovigilance

To be competent, the user/individual on the job must be able to:

- **PC6.** participate in discussions and answer questions related to signal detection methods in pharmacovigilance.
- **PC7.** evaluate their knowledge of benefit-risk assessment in pharmacovigilance

Risk Minimization and Compliance for Pharmacovigilance

To be competent, the user/individual on the job must be able to:

- **PC8.** Identify and evaluate various risk minimization strategies applicable to different contexts within the pharmaceutical industry.
- **PC9.** Prepare a sample comprehensive risk minimization plans for hypothetical scenarios, considering diverse risk factors and potential mitigations
- **PC10.** Apply theoretical knowledge to real-world scenarios by creating a detailed risk minimization plan for a hypothetical drug
- PC11. Engage in a simulated audit scenario to identify and address compliance challenges

Application and Emerging Technologies For Pharmacovigilance

To be competent, the user/individual on the job must be able to:









- **PC12.** Evaluate the impact of ethical decisions on public health and regulatory compliance.
- **PC13.** Apply CAPA principles through a demonstration study, identifying and addressing compliance issues effectively
- **PC14.** Evaluate the potential benefits and challenges associated with integrating Al and blockchain technologies into aggregate reporting processes.
- **PC15.** Evaluate case studies and examples illustrating the successful integration of Al and blockchain in pharmacovigilance

#### **Knowledge and Understanding (KU)**

The individual on the job needs to know and understand:

- **KU1.** Understanding the roles and responsibilities of regulatory authorities in overseeing drug safety.
- **KU2.** IT policies of company
- **KU3.** data integrity related SOPs
- **KU4.** SOP for accessing the computer systems and emails
- **KU5.** procedures for reporting data, escalation procedures
- **KU6.** quality management SOPs including those for change control, deviations and CAPAs and BCP
- **KU7.** basic of aggregrate reports
- **KU8.** operating procedure of software like MedDRA, WHO Drug dictionary, SAS, various Drug Safety Database like Argus and ArisGlobal, Safety Easy (AB Cube), EudraVigilance and ADR reporting software like VigiFlow and VigiBase
- KU9. GCP guidelines and ICH E2B standard
- **KU10.** computer handling (MS Word, Excel, Power Point Presentation, Outlook and Skype)
- **KU11.** software validation procedures
- **KU12.** Changes/new regulations affecting pharmacovigilance activities
- **KU13.** method of writing case narratives and medical writing
- KU14. tools and methods of literature search
- **KU15.** process flow and forms of ADR reporting reports
- **KU16.** artificial intelligence future software validation tools (IQ, OQ & PQ) as well as about artificial intelligence
- **KU17.** changes/new regulations affecting pharmacovigilance activities
- **KU18.** assessment of Vaccine Adverse Event Reporting System (VAERS)
- KU19. recall International Classification of Diseases (ICD) codes for drugs
- **KU20.** Understanding the challenges and potential solutions for the integration of AI into regulatory compliance processes
- **KU21.** Classifying adverse events into different categories, including serious, non-serious, expected, and unexpected.
- **KU22.** Understanding the various sources of adverse event data, such as spontaneous reports, data from clinical trials, and information from social media.
- **KU23.** Recognizing the importance of data quality and reliability in the context of pharmacovigilance.









#### **Generic Skills (GS)**

User/individual on the job needs to know how to:

- **GS1.** use reading and comprehension skills to read instructions, guidelines, procedures, rules, and signages
- **GS2.** use written communication skills to accurately record every information required to be reported as per SOP and regulatory guidelines in the language prescribed by the company's SOP
- **GS3.** apply planning and organizing skills to plan and organize tools and material required for work to fulfil environment, health, safety and security requirements
- **GS4.** apply customer centricity to remain compliant with data integrity rules and regulatory guideline to evaluate impact of wrongdoings
- **GS5.** apply decision-making skills to make balanced judgments within the authority in different situations while dealing with hazards and breaches
- **GS6.** apply problem-solving skills to find solutions for workflow-related difficulties
- **GS7.** use verbal communication skills to communicate with supervisor/ manager/ Incharge or any other concerned authority clearly for escalating any emergency situation or hazard
- **GS8.** draft letters pertaining to AEs and write detailed reports for pharmacovigilance reporting
- **GS9.** record and communicate details of work done to appropriate people using written/typed report or computer-based record/electronic mail
- **GS10.** use computers, internet, software tools for pharmacovigilance related work
- **GS11.** read and interpret various coding systems, medical terminology as per company norms, GCP, PVPI and WHO guidelines
- **GS12.** read notes/comments from supervisors
- **GS13.** disclose information only to those who have the right and need to know it
- **GS14.** maintain confidentiality of sensitive information
- **GS15.** communicate new or changed regulations to relevant members of the department to initiate any change in process
- **GS16.** build and maintain good relationships across functional units and company affiliates
- **GS17.** analyse data and information for preparing reports
- **GS18.** pay attention to detail
- GS19. identify anomalies in data
- **GS20.** suggest improvements (if any) in process/formats for reports/documentation based on experience and observation
- **GS21.** use available data and computer software to create required documentation
- **GS22.** make decisions on a suitable course of action or response
- **GS23.** make decisions to write case narratives in compliance to the regulations and guidelines
- **GS24.** plan and organize assigned work in order to achieve specified deadlines
- **GS25.** multi-task and adapt to meet work timelines
- **GS26.** effectively interact with the various stakeholders to complete assigned tasks
- **GS27.** evaluate the drafted reports in line to data integrity rules
- **GS28.** critically assess the terms/ medical codes for preparing the report









- GS29. take help of IT team in case of any login related issues
- GS30. escalate critical items or any other issue deemed necessary to concerned managers/ clients
- **GS31.** keep customer guidelines, instructions and the relevant regulatory guidelines in focus while reporting the ADR
- **GS32.** ensure data integrity and confidentiality while entering information
- **GS33.** liaise effectively and maintain excellent relationship with the internal/external contacts









### **Assessment Criteria**

| Assessment Criteria for Outcomes  | Theory<br>Marks | Practical<br>Marks | Project<br>Marks | Viva<br>Marks |
|---|-----------------|--------------------|------------------|---------------|
| Life sciences industry and Aggregate Reports  | 5               | 5                  | -                | -             |
| <b>PC1.</b> analyze a sample Aggregate Report and discuss a case study on regulatory compliance in pharmacovigilance  | -               | -                  | -                | -             |
| <b>PC2.</b> outline data sources and their management in pharmacovigilance  | -               | -                  | -                | -             |
| Report Structure and Writing Skills for pharmacovigilance reporting   | 10              | 10                 | -                | -             |
| <b>PC3.</b> submit a written assignment with sections of Aggregate Reports based on provided templates to demonstrate their understanding of report structure and regulatory writing. | -               | -                  | -                | -             |
| <b>PC4.</b> Participate in group exercises to collaboratively create a comprehensive Aggregate Report section, which will be evaluated for completeness and regulatory compliance.    | -               | -                  | -                | -             |
| <b>PC5.</b> explore best practices in writing skills for regulatory compliance  | -               | -                  | -                | -             |
| Signal Detection and Evaluation for<br>Pharmacovigilance  | 12              | 13                 | -                | -             |
| <b>PC6.</b> participate in discussions and answer questions related to signal detection methods in pharmacovigilance.   | -               | -                  | -                | -             |
| <b>PC7.</b> evaluate their knowledge of benefit-risk assessment in pharmacovigilance  | -               | -                  | -                | -             |
| Risk Minimization and Compliance for<br>Pharmacovigilance   | 13              | 12                 | -                | -6            |
| <b>PC8.</b> Identify and evaluate various risk minimization strategies applicable to different contexts within the pharmaceutical industry.   | -               | -                  | -                | -             |
| <b>PC9.</b> Prepare a sample comprehensive risk minimization plans for hypothetical scenarios, considering diverse risk factors and potential mitigations                             | -               | -                  | -                | -             |









| Assessment Criteria for Outcomes   | Theory<br>Marks | Practical<br>Marks | Project<br>Marks | Viva<br>Marks |
|--|-----------------|--------------------|------------------|---------------|
| <b>PC10.</b> Apply theoretical knowledge to real-world scenarios by creating a detailed risk minimization plan for a hypothetical drug                     | -               | -                  | -                | -             |
| <b>PC11.</b> Engage in a simulated audit scenario to identify and address compliance challenges  | -               | -                  | -                | -             |
| Application and Emerging Technologies For<br>Pharmacovigilance   | 10              | 10                 | -                | -             |
| <b>PC12.</b> Evaluate the impact of ethical decisions on public health and regulatory compliance.  | -               | -                  | -                | -             |
| <b>PC13.</b> Apply CAPA principles through a demonstration study, identifying and addressing compliance issues effectively                                 | -               | -                  | -                | -             |
| <b>PC14.</b> Evaluate the potential benefits and challenges associated with integrating Al and blockchain technologies into aggregate reporting processes. | -               | -                  | -                | -             |
| <b>PC15.</b> Evaluate case studies and examples illustrating the successful integration of Al and blockchain in pharmacovigilance                          | -               | -                  | -                | -             |
| NOS Total  | 50              | 50                 | -                | -             |









# **National Occupational Standards (NOS) Parameters**

| NOS Code                                       | LFS/N0708   |
|--|---|
| NOS Name                                       | Aggregate Report writing for Regulatory Compliance  |
| Sector   | Life Sciences   |
| Sub-Sector                                     | Pharmaceutical, Bio Pharmaceutical, Contract Research   |
| Occupation                                     | Pharmacovigilance   |
| NSQF Level                                     | 5.5   |
| Credits  | 2.0   |
| Minimum Job Entry Age                          | NA  |
| Minimum Educational Qualification & Experience | Pursuing 3rd year of UG (B.Sc (Microbiology) ) OR Pursuing 4th year UG (in case of 4-year UG with honours/ honours with research) (B. Pharma / B. Tech (Biotech) (Indian / foreign universities) ) OR Medical Graduate (Pursuing Final Year of MBBS/BDS/BPT/BOT/BAMS/BHMS (in any medical subject)/ (Indian / recognized foreign universities)) |
| Version  | 1.0   |
| Last Reviewed Date                             | 01/11/2023  |
| Next Review Date                               | 01/11/2026  |
| NSQC Clearance Date                            | 01/11/2023  |
| Reference code on NQR                          | NG-5.5-LS-01296-2023-V1-LSSSDC  |
| NQR Version                                    | 1   |
| CCN Category                                   | 2   |